Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Rimegepant Sulfate

FDA-approved product (tablet, orally disintegrating, oral), marketed as Nurtec Odt.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Rimegepant Sulfate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Migraine disorder

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Calcitonin gene-related peptide (cgrp) antagonists
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA64.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli61.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae40.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis60.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Rimegepant Sulfate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Rimegepant Sulfate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Randomized, Open-Label, Multi-Center Study of Vestibular Migraine Prevention: Rimegepant Versus Flunarizine Non-inferiority Study

    NCT07751497 · start 2026-12-01

    Registered record
    Registry ID
    NCT07751497
    Conditions
    Vestibular Migraine
    Interventions
    Rimegepant; Flunarizine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-12-01
    Completion
    2029-04-01
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVestibular Migraine
    InterventionRimegepant; Flunarizine
    PhasePhase 2
    Registry statusNot yet recruiting

  • A Study to Learn About the Study Medicine NURTEC® ODT 75 mg After it is Released Into the Markets in Korea

    NCT07497854 · start 2026-10-01

    Registered record
    Registry ID
    NCT07497854
    Conditions
    Migraine With or Without Aura
    Interventions
    Rimegepant sulfate
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2026-10-01
    Completion
    2030-08-01
    Enrolment
    3,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine With or Without Aura
    InterventionRimegepant sulfate
    PhaseNot recorded
    Registry statusNot yet recruiting

  • Rimegepant For Endometriosis Pain

    NCT07795125 · start 2026-09-30

    Registered record
    Registry ID
    NCT07795125
    Conditions
    Endometriosis; Endometriosis-related Pain
    Interventions
    Rimegepant 75 MG; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-09-30
    Completion
    2031-09-30
    Enrolment
    132

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndometriosis; Endometriosis-related Pain
    InterventionRimegepant 75 MG; Placebo
    PhasePhase 2
    Registry statusNot yet recruiting

  • Biological Profiles of Neuropeptides, Neurotrophins and miRNA in Migraine

    NCT07832032 · start 2026-09-17

    Registered record
    Registry ID
    NCT07832032
    Conditions
    Migraine
    Interventions
    Rimegepant 75 MG
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2026-09-17
    Completion
    2027-12-31
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine
    InterventionRimegepant 75 MG
    PhaseNot recorded
    Registry statusNot yet recruiting

  • A Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine

    NCT07729462 · start 2026-08-26

    Registered record
    Registry ID
    NCT07729462
    Conditions
    Preventive Treatment of Migraine
    Interventions
    Rimegepant; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2026-08-26
    Completion
    2029-01-19
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPreventive Treatment of Migraine
    InterventionRimegepant; Placebo
    PhasePhase 3
    Registry statusRecruiting

  • A Prospective, Open-Label Study Evaluating the Effectiveness of Gepants for Acute Treatment of Migraine in the Emergency Department

    NCT07667621 · start 2026-07

    Registered record
    Registry ID
    NCT07667621
    Conditions
    Migraine; Migraine Disease; Migraine in Adults; Migraine Headache; Acute Migraine; Migraine Without Aura; Migraine With Aura
    Interventions
    Rimegepant; Zavegepant
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Not yet recruiting
    Start
    2026-07
    Completion
    2027-08
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine; Migraine Disease; Migraine in Adults; Migraine Headache +3 more
    InterventionRimegepant; Zavegepant
    PhasePhase 1
    Registry statusNot yet recruiting

  • Rimegepant Plus Glofitamab and CD19 CAR-T Therapy in R/R LBCL

    NCT07613788 · start 2026-05

    Registered record
    Registry ID
    NCT07613788
    Conditions
    Relapsed/Refractory Large B-cell Lymphoma (LBCL)
    Interventions
    Rimegepant; Glofitamab; Obinutuzumab; CD19 CAR-T Cell Therapy; Fludarabine; Cyclophosphamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-05
    Completion
    2029-04
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRelapsed/Refractory Large B-cell Lymphoma (LBCL)
    InterventionRimegepant; Glofitamab; Obinutuzumab; CD19 CAR-T Cell Therapy +2 more
    PhasePhase 2
    Registry statusNot yet recruiting

  • Efficacy and Safety of Rimegepant for Acute Dizziness

    NCT07435090 · start 2026-03-20

    Registered record
    Registry ID
    NCT07435090
    Conditions
    Dizziness
    Interventions
    Rimegepant 75mg Orally Disintegrating Tablets (ODT); Betahistine Mesylate tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-03-20
    Completion
    2028-06-30
    Enrolment
    370

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDizziness
    InterventionRimegepant 75mg Orally Disintegrating Tablets (ODT); Betahistine Mesylate tablet
    PhasePhase 2 / Phase 3
    Registry statusNot yet recruiting

  • Rimegepant Combined With AG Chemotherapy As First-Line Treatment For Metastatic Pancreatic Ductal Adenocarcinoma

    NCT07475234 · start 2026-03

    Registered record
    Registry ID
    NCT07475234
    Conditions
    Metastatic Pancreatic Ductal Adenocarcinoma
    Interventions
    Rimegepant plus Nab-Paclitaxel and Gemcitabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-03
    Completion
    2028-12
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Pancreatic Ductal Adenocarcinoma
    InterventionRimegepant plus Nab-Paclitaxel and Gemcitabine
    PhasePhase 1 / Phase 2
    Registry statusNot yet recruiting

  • Rimegepant as Preemptive Treatment for Predictable Trigger-Induced Migraine in Adult Patients in the US

    NCT07301008 · start 2025-09-09

    Registered record
    Registry ID
    NCT07301008
    Conditions
    Migraine; Trigger Induced Migraine
    Interventions
    Rimegepant 75 MG
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2025-09-09
    Completion
    2027-01
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine; Trigger Induced Migraine
    InterventionRimegepant 75 MG
    PhasePhase 4
    Registry statusRecruiting

  • A Clinical Trial of Rimegepant for Vestibular Migraine Evaluation: Pre-experiment

    NCT06748664 · start 2025-06-01

    Registered record
    Registry ID
    NCT06748664
    Conditions
    Vestibular Migraine; Adults 18 Years and Older (no Other Exclusion Criteria)
    Interventions
    Rimegepant; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2025-06-01
    Completion
    2027-05-01
    Enrolment
    240

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVestibular Migraine; Adults 18 Years and Older (no Other Exclusion Criteria)
    InterventionRimegepant; Placebo
    PhasePhase 2
    Registry statusNot yet recruiting

  • The R-E-V-I-V-A-L Study

    NCT06992674 · start 2025-06-01

    Registered record
    Registry ID
    NCT06992674
    Conditions
    Vestibular Migraine
    Interventions
    Rimegepant; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2025-06-01
    Completion
    2026-12-01
    Enrolment
    240

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVestibular Migraine
    InterventionRimegepant; Placebo
    PhasePhase 2
    Registry statusActive not recruiting

  • A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine

    NCT06641466 · start 2025-03-11

    Registered record
    Registry ID
    NCT06641466
    Conditions
    Menstrual Migraine
    Interventions
    Rimegepant; Placebo Comparator; Standard of Care; Rimegepant
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-03-11
    Completion
    2027-03-30
    Enrolment
    723

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMenstrual Migraine
    InterventionRimegepant; Placebo Comparator; Standard of Care; Rimegepant
    PhasePhase 3
    Registry statusRecruiting

  • The Real-world Study of Rimegepant Treatment in Female Migraine Patients of China

    NCT06728345 · start 2024-12-01

    Registered record
    Registry ID
    NCT06728345
    Conditions
    Migraine; Migraine Prophylaxis
    Interventions
    Rimegepant
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2024-12-01
    Completion
    2027-12-31
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine; Migraine Prophylaxis
    InterventionRimegepant
    PhaseNot recorded
    Registry statusNot yet recruiting

  • A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine

    NCT06616194 · start 2024-11-15

    Registered record
    Registry ID
    NCT06616194
    Conditions
    Migraine
    Interventions
    Rimegepant; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2024-11-15
    Completion
    2029-10-13
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine
    InterventionRimegepant; Placebo
    PhasePhase 3
    Registry statusActive not recruiting